NCT04234607 - A Study of TQB2450 or Placebo Combined With Anlotinib, Etoposide and Carboplatin Versus Etoposide and Carboplatin in Subjects With Extensive Small Cell Lung Cancer (ETER701) | Biotech Hunter

Enrollment

738

Participants

Timeline

Start Date

January 31, 2020

Primary Completion Date

December 31, 2022

Study Completion Date

December 31, 2022

Conditions

Extensive Small Cell Lung Cancer

Interventions

DRUG

TQB2450

TQB2450 is a humanized monoclonal antibody targeting programmed death ligand-1 (PD-L1), which prevents PD-L1 from binding to PD-1 and B7.1 receptors on T cell surface, restores T cell activity, thus enhancing immune response and has potential to treat various types of tumors.

DRUG

Anlotinib

a multi-target receptor tyrosine kinase inhibitor

DRUG

Etoposide

Etoposide is a cell cycle-specific antitumor drug

DRUG

Carboplatin

Carboplatin is cell cycle nonspecific antitumor drug

DRUG

TQB2450（blank）

Subjects administrated TQB2450 (blank) intravenously (IV) on Day 1 of each 21-day

DRUG

Anlotinib（blank)

Subjects administrated anlotinib (blank) in fasting conditions, once daily in 21-day cycle (14 days on treatment from Day 1-14, 7 days off treatment from Day 15-21)

Trial Locations (26)

101149

Beijing chest hospital，capital medical university, Beijing

116027

The Second Hospital of Dalian Medical University, Dalian

130000

Jilin Cancer Hospital, Changchun

150000

Harbin Medical University Cancer Hospital, Harbin

222000

The First People's Hospital of Lianyungang, Lianyungang

230001

Anhui chest hospital, Hefei

AnHui Provincial Hospital, Hefei

The First Affiliated Hospital of Anhui Medical University, Hefei

The Second Affiliated Hospital of Anhui Medical University, Hefei

233000

The First Affiliated Hospital of Bengbu Medical College, Bengbu

350001

Fujian Medical University Union Hospital, Fuzhou

350011

Fujian Provincial Cancer Hospital, Fuzhou

410006

Hunan Cancer Hospital, Changsha

434020

Jinzhou Central Hospital, Jinzhou

450008

Henan Cancer Hospital, Zhengzhou

510120

The First Affiliated Hospital of Guangzhou Medical University, Guangzhou

510405

The Fiest Affiliated Hospital of Guanghzou University of Chinese Medicine, Guangzhou

518036

Peking University Shenzhen Hospital, Shenzhen

524000

Affiliated Hospital of Guangdong Medical University, Zhanjiang

530000

Guangxi Medical University Affiliated Tumor Hospital, Nanning

550002

Guizhou Provincial people's Hospital, Guiyang

570100

The Second Affiliated Hospital of Hainan Medical University, Haikou

730030

Lanzhou University Second Hospital, Lanzhou

730050

Gansu Provincial Cancer Hospital, Lanzhou

050011

Shijiazhuang First Hospital, Shijiazhuang

050048

Hebei Chest Hospital, Shijiazhuang